0001437749-24-008748.txt : 20240320
0001437749-24-008748.hdr.sgml : 20240320
20240320200348
ACCESSION NUMBER: 0001437749-24-008748
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240318
FILED AS OF DATE: 20240320
DATE AS OF CHANGE: 20240320
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lo Steven
CENTRAL INDEX KEY: 0001501959
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35285
FILM NUMBER: 24769140
MAIL ADDRESS:
STREET 1: C/O CORCEPT THERAPEUTICS
STREET 2: 149 COMMONWEALTH DRIVE
CITY: MENLO PARK
STATE: CA
ZIP: 94010
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Vaxart, Inc.
CENTRAL INDEX KEY: 0000072444
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 591212264
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 170 HARBOR WAY, SUITE 300
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: (650) 550-3500
MAIL ADDRESS:
STREET 1: 170 HARBOR WAY, SUITE 300
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
FORMER COMPANY:
FORMER CONFORMED NAME: Aviragen Therapeutics, Inc.
DATE OF NAME CHANGE: 20160413
FORMER COMPANY:
FORMER CONFORMED NAME: Biota Pharmaceuticals, Inc.
DATE OF NAME CHANGE: 20121113
FORMER COMPANY:
FORMER CONFORMED NAME: NABI BIOPHARMACEUTICALS
DATE OF NAME CHANGE: 20100719
4
1
rdgdoc.xml
FORM 4
X0508
4
2024-03-18
0000072444
Vaxart, Inc.
VXRT
0001501959
Lo Steven
C/O VAXART, INC.
170 HARBOR WAY, SUITE 300
SOUTH SAN FRANCISCO
CA
94080
1
1
President, Chief Exec Officer
0
Common Stock
2024-03-18
4
A
0
250000
0
A
250000
D
Stock Option (right to buy)
1.16
2024-03-18
4
A
0
1000000
0
A
2034-03-17
Common Stock
1000000
1000000
D
Grant of shares upon vesting of restricted stock units. Twenty five percent of the shares underlying the award shall vest on each anniversary of the vesting commencement date of March 18, 2024, so that the restricted stock units would be fully vested on the fourth anniversary of the vesting commencement date.
The shares subject to this stock option shall vest as to 25% of the shares underlying the grant on March 18, 2025, the first anniversary of the date that vesting commenced, and thereafter in 36 equal monthly installments such that the stock option shall be fully vested on March 18, 2028.
/s/ Edward Berg, Attorney-in-Fact
2024-03-20